Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | IL18 | Q14116 | 1/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884691 | 0.83 | IDO1 (0.67) | IDO1TAS2R38MAPTLMNADHODH | |
| SCHEMBL5449567 | 0.83 | IDO1 (0.78) | IDO1TAS2R38MAPTLMNADHODH | |
| SCHEMBL14511451 | 0.82 | TAS2R38 (0.75) | TAS2R38MAPTTSHRHTTMEN1 | |
| SCHEMBL27309231 | 0.82 | IDO1 (0.65) | IDO1TAS2R38MAPTLMNADHODH | |
| SCHEMBL23866977 | 0.80 | IDO1 (0.58) | IDO1MAPTLMNADHODHTSHR | |
| SCHEMBL10514730 | 0.80 | IDO1 (0.68) | IDO1MAPTLMNADHODHTSHR | |
| SCHEMBL1344408 | 0.79 | KDM1A (0.71) | IDO1MAPTLMNATSHRHTT | |
| SCHEMBL1085552 | 0.79 | IDO1 (0.52) | IDO1MAPTLMNADHODHTSHR | |
| SCHEMBL8956175 | 0.79 | IDO1 (0.66) | IDO1MAPTDHODHHTTMEN1 | |
| SCHEMBL20809397 | 0.79 | IDO1 (0.56) | IDO1MAPTLMNADHODHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-14 | — | — | US | disclosed |
| WO-2017070229-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| US-5149814-A | Alkyl 2-benzylidene-4-(2-alkylimidazopyrid-1-yl) benzoylacetate esters as intermediate compounds | PFIZER INC (US) | 1992-09-22 | — | — | US | disclosed |
| US-5120747-A | Antiallergens, antiinflammatory agent | PFIZER INC. (US) | 1992-06-09 | — | — | US | disclosed |
| US-5070205-A | Chemical intermediate for anticoagulants | PFIZER INC. (US) | 1991-12-03 | — | — | US | disclosed |
| EP-0310386-B1 | 4-ARYL-5-CARBAMOYL-1,4-DIHYDROPYRIDINES | Pfizer Limited (GB) | 1991-11-06 | — | — | EP | disclosed |
| US-5063237-A | Antiallergens and antiinflammatory agents | PFIZER INC. (US) | 1991-11-05 | — | — | US | disclosed |
| US-4935430-A | Platelet activating factor antagonists | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0310386-A2 | 4-Aryl-5-carbamoyl-1,4-dihydropyridines | Pfizer Limited (GB) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | GAP43, NCDN, NLN | IDO1 3037/4885TAS2R38 4156/4885MAPT 588/4885 |
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | GAP43, NCDN, NLN | IDO1 3037/4885TAS2R38 4156/4885MAPT 588/4885 |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | IDO1 1771/4885TAS2R38 2725/4885MAPT 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.